Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Stage

Acquired Unit | Acquired

Valuation

$0000 

About Xoma (XOMA) - Antibody Manufacturing Pilot Plant and Capabilities

XOMA (NASDAQ: XOMA) is a biotechnology company focused on the discovery and development of monoclonal antibody-based therapeutics. The Company is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. XOMA's innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.

Xoma (XOMA) - Antibody Manufacturing Pilot Plant and Capabilities Headquarter Location

2910 Seventh Street

Berkeley, California, 94710,

United States

510-204-7200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Xoma (XOMA) - Antibody Manufacturing Pilot Plant and Capabilities

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Xoma (XOMA) - Antibody Manufacturing Pilot Plant and Capabilities is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.